What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

Related Articles

Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC)

6 months ago

What Prompted Vivo Capital's Exit from Cidara Therapeutics

4 months ago

What Drove Dianthus Therapeutics' Recent Stock Surge

6 months ago

OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

2 months ago

Category

You may also like

News•1 week ago

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios...

Share

Stock News•1 months ago

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears

NewAmsterdam Pharma outlined its obicetrapib cardiovascular strategy at Investor Day, updating clinical programs and commercial prep ahead of a potential European launch, as the PREVAIL interim readou...

NAMS

Share

Stock News•2 months ago

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

ProQR Therapeutics' RNA editing platform achieved human pharmacological activity with AX-0810 Phase 1 target engagement data. A $50M direct offering and Eli Lilly's $9.2M investment extend cash runway...

PRQR

Share